Landscape of Measurable Residual Disease in Acute Myeloid Leukemia: From Molecular Detection to Clinical Practice
Open Access
- 5 March 2026
- journal article
- review article
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 123
Abstract
Measurable residual disease (MRD) has become a central determinant of prognosis and treatment planning in acute myeloid leukemia (AML). MRD assessment is now aided by a wide range of technologies, including next-generation sequencing, PCR-based assays, multiparameter flow cytometry, and emerging approaches such as liquid biopsy platforms and imaging-based detection. These modalities differ in sensitivity, applicability, and interpretive framework, yet each offers distinct advantages in specific disease contexts. Beyond technical issues, MRD is becoming increasingly integrated into clinical practice. In non-intensive treatment settings, where targeted and low-intensity regimens rely on dynamic disease monitoring to guide ongoing management, MRD is increasingly being used to inform therapeutic decisions. In the peri-transplant setting, MRD status influences conditioning strategies, donor selection, and the use of post-transplant interventions. Despite the growing evidence supporting the clinical relevance of MRD across these scenarios, challenges remain regarding standardization, optimal timing of assessment, and the interpretation of discordant results. This review summarizes the full landscape of MRD detection methods and examines the evolving role of MRD in contemporary AML management, emphasizing current applications and areas requiring further refinement.Keywords
This publication has 103 references indexed in Scilit:
- Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug developmentAmerican Journal of Hematology, 2024
- Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panelAmerican Journal of Hematology, 2023
- DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantJAMA, 2023
- Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approachAmerican Journal of Hematology, 2022
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid LeukemiaJAMA Oncology, 2020
- Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal ApproachCurrent Protocols in Cytometry, 2020
- Clonal evolution of acute myeloid leukemia from diagnosis to relapseGenes, Chromosomes and Cancer, 2019
- Identifying leukemia‐associated immunophenotype‐based individualized minimal residual disease in acute myeloid leukemia and its prognostic significanceAmerican Journal of Hematology, 2019
- Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaAmerican Journal of Hematology, 2017